We investigated whether or not human disease-causing, amino acid substitutions in MYH9 could cause dominant phenotypes when introduced into the sole nonmuscle myosin II heavy chain in Drosophila melanogaster (zip/MyoII). We characterized in vivo the effects of four MYH9-like mutations in the myosin rod -R1171C, D1430N, D1847K and R1939X -which occur at highly conserved residues. These engineered mutant heavy chains resulted in D.
Introduction
MYH9 encodes one of three nonmuscle myosin II heavy chains in humans (MYH9 encodes IIA, MYH10 encodes IIB and MYH14 encodes IIC). Mutations in MYH9 cause several autosomal dominant, giant-platelet disorders that are collectively known as MYH9-related disorders (1) (2) (3) (4) (5) (6) (7) . Virtually all individuals with this disorder exhibit platelet macrocytosis (enlarged platelets), thrombocytopenia (reduced platelet number), and leukocyte inclusions. Mutations in MYH9 also cause less penetrant, nonhematologic manifestations -high-tone, sensorineural deafness; cataracts; and nephritis. The severity and occurrence of these symptoms vary among individuals, can be life threatening and are likely due to the effects of variable genetic backgrounds (e.g., they have polymorphic loci that genetically interact with MYH9).
Identification of such polymorphic loci is extremely difficult and time intensive to study in humans. The development of a disease model in a genetically tractable organism with fast generation time, facile genetic screening approaches, and straightforward identification of interacting loci could prove extremely useful in the identification of factors that contribute to the variable clinical manifestations. Further, the ability to screen potential drug and therapeutic treatments in a model organism is very attractive.
Functional myosin II heavy chains, including those encoded by MYH9, are normally incorporated into heterohexameric motor molecule complexes, which consist of two heavy chains and two pairs of light chains ( Figure 1A ). Each myosin II heavy chain can be divided into three regions or domains: a globular head or motor domain, which is responsible for actin binding and ATP hydrolysis; a neck region, which is important for regulation, light chain binding and functions as a lever arm critical for chemomechanical force production; and a rod, or tail, region, which is responsible for dimerization and filament formation. Native myosin II heterohexamers self-assemble into bipolar, or side-polar, filaments in order to generate forces for the displacement of antiparallel actin filaments. Myosin II filament assembly is specified and mediated by sequences in the rod region (8) (9) (10) (11) (12) and requires at least two conceptually distinct steps (that may overlap temporally). First, a heptad repeat mediates the dimerization of individual heavy chains by correctly folding the nascent polypeptide chains into the α-helical coiled-coil structure, which constitutes the extended rod-like tail that characterizes all myosin IIs.
Second, charge distributions along the length of each coiled-coil dimer ensures that correct lateral associations occur such that individual myosin molecules align in proper register and orientation to form functional side polar filaments under physiological salt conditions (at high salt, filaments do not assemble, 9, 10).
Disease-causing mutations in MYH9 (as well as mutations in other myosin II heavy chains causing disease) are present in sequences that span the entire heavy chain. Approximately 75% of MYH9-related disorder families have mutations in the rod region (13) . Despite the large number of mutations identified in the rod, 88% of all MYH9 rod mutations occur at four residues (amino acids 1165, 1424, 1841 and 1933, see references 1, 6, 13, 14) . These include identical mutations in unrelated families and different amino acid changes at the same amino acid residue (e.g., amino acids 1165 and 1424, specifically R1165 to C or L and D1424 to N, H or Y).
Together, this suggests these mutations cause highly specific disruptions of nonmuscle myosin IIA structure and/or function and have arisen as the consequence of independent mutagenic events.
The specific biochemical mechanisms that account for how these mutations disrupt myosin II structure and/or function to cause disease are incompletely understood. Two mechanisms have been proposed for MYH9-related disorder mutations. The first proposes that mutant heavy chains are unstable, are degraded by the cell, and the observed hematologic manifestations are the result of haploinsufficiency (15, 16) . The second possibility is that mutant heavy chains have a dominant activity and inhibit the ability of wild-type heavy chain to perform cellular functions at wild-type levels. This could occur by 1) disrupting the assembly of bipolar filaments, 2) impairing the ability of bipolar filaments to properly translocate actin filaments or 3) by sequestering wild-type heavy chain away from sites of activity.
Using recombinant approaches, Sellers and colleagues showed that heavy meromyosin (HMM) fragments, which include the catalytic head and light chain binding domains, containing either of two MYH9 head mutations (N93K and R702C) have impaired enzymatic activity and that their ability to translocate actin filaments in vitro is significantly reduced compared with wild type (17) . Similar in vitro experiments on HMM fragments containing mutations analogous to the N93K and R702C MYH9 mutations engineered in the human MYH10 (nonmuscle myosin IIB; N97K and R709C respectively) and mouse Myh14 (nonmuscle myosin IIC; R722C and R730C respectively) resulted in reduced enzymatic activity and actin filament sliding (18) .
Precisely how reduced enzyme activity and actin filament sliding causes a dominant pathology is not known, but it is reasonable to suspect that impaired myosin head function in a heterologous filament that contains both wild-type and mutant heads might compromise myosin driven contractility in a dominant fashion.
Using recombinant approaches, we previously showed that the four most common rod mutations (R1165C, D1424N, E1841K and R1933X) were found to directly affect assembly of tail fragments into higher-ordered assemblies by one of two distinct mechanisms (19) . Two mutants (R1165C and E1841K) had decreased folding into a wild-type coiled-coil structure while two (D1424N and 1933X) had intact coiled-coil structure but native myosin II dimers were unable to laterally associate properly to form wild-type higher-order structures (19) . The effect that mutations analogous to those in the MYH9 rod that cause disease have on other myosin II heavy chains remains unknown and is the subject of this investigation.
Mutations in other human conventional myosin (i.e., myosin II) heavy chains, including skeletal, cardiac and nonmuscle isoforms, are responsible for a number of autosomal dominant pathologies (Table 1, melanogaster (21) (22) (23) . As in other metazoans, functional nonmuscle myosin II is necessary in D.
melanogaster for cytokinesis, proper subcellular localization of cell-fate determinants during certain asymmetric cell divisions and numerous morphogenic movements during development (22, (25) (26) (27) 
Results

MYH9-like mutant zip/MyoII heavy chain transgenes
To explore the use of Drosophila melanogaster as a model system for MYH9-related disorders, we constructed transgenes in which highly conserved rod residues in its sole nonmuscle myosin II heavy chain (zip/MyoII) were replaced with analogous mutant residues that cause MYH9-related disorders in humans. We previously generated an N-terminal GFP-tagged Figure 1B ), D1430N (corresponds to D1424N in MYH9, Figure 1C ), D1847K (corresponds to E1841K in MYH9, Figure 1D ) and R1939X (corresponds to R1933X in MYH9, Figure 1E heterozygous zip/MyoII genetic background. We cannot rule out that some minor, dominant effects might occur when mutant heavy chains are expressed in these animals and that the assays we used were not sufficiently sensitive to detect them. For example, our phenotypic inspection of whole flies would miss minor but real hematological defects in flies that would be comparable to the hematological defects seen in MYH9-related disorder patients. We found that all MYH9-like zip/MyoII mutant heavy chains had some wild-type activity -they were able to rescue the early, embryonic lethal phenotype at a frequency comparable to a wild-type, GFP-zip/MyoII transgene (GFP-zip/MyoII R1171C = 80% +/-8%, GFP-zip/MyoII D1430N = 93% +/-4%, GFP-zip/MyoII D1847K = 88% +/-4% and GFP-zip/MyoII R1939X = 91% +/-3%; compared to rescue with the wild-type transgene; GFP-zip/MyoII WT = 92% +/-2%; Table 2B ). In addition, many rescued larvae went on to complete subsequent larval and pupal development.
MYH9-like
Based on these results we concluded that all of the examined MYH9-like rod mutations in zip/MyoII produced stable heavy chains that lacked any direct dominant negative activity. These rescue results also demonstrate that the sqh-Gal4 driver (sqh encodes the regulatory light chain of zip/MyoII), the only nonmuscle myosin II Gal4 driver available, was appropriate for ubiquitous expression. We also assayed the relative amount of each GFP-zip/MyoII heavy chain present in rescued animals compared to the amount of endogenous zip/MyoII in wild type animals (see Supplementary Material). We found that GFP-zip/MyoII heavy chain expression was similar, or greater than, endogenous zip/MyoII protein levels.
Interestingly, three of the GFP-zip/MyoII mutant heavy chains (D1430N, D1847K or R1939X) failed to rescue later developmental stages (adult eclosing flies) at frequencies comparable to the GFP-zip/MyoII WT control (Table 2B ). To verify these findings, we performed similar rescue analysis on different P-element insertions of the GFP-zip/MyoII D1430N or D1847K transgenes and found similar results (for both D1430N and D1847K, none of the 150 selected embryos went on to eclose as adult flies).
We also found that the overall rate of development was reduced in animals rescued with any GFP-zip/MyoII mutant heavy chain compared to those animals rescued with GFP-
zip/MyoII
WT . Animals rescued with mutant heavy chains generally began pupation one day later than GFP-zip/MyoII WT rescued animals and when and if adult flies did eclose they did so at least two days later than GFP-zip/MyoII WT rescued animals.
Thus, GFP-zip/MyoII mutant heavy chains only partially rescue zip/MyoII-deficient animals (Table 2B ) and behave as partial, loss of function, recessive alleles. They lack severe, and overt, dominant phenotypes when expressed in wild-type and heterozygous heavy chain backgrounds (Table 2A) .
MYH9-like zip/MyoII heavy chains function as special zip/MyoII alleles that can be used to
identify second site, non-complementing (SSNC) loci.
We next examined whether or not these zip/MyoII MYH9 alleles resulted in a sensitized genetic background that enable the in vivo identification of genetically interacting loci. We found that each MYH9-like zip/MyoII heavy chain exhibited second-site noncomplementation (Table   3 ). Each GFP-zip/MyoII mutant heavy chain was expressed in a genetic background that was designed to mimic the genotypes we and others originally used to demonstrate second site non- ; see Table 3 ; Figure 2 ). Some animals had both malformed legs and wings while others showed only malformed wing phenotypes. For several reasons we believe that the phenotypes are the result of a specific genetic interaction with MYH9-like heavy chains. First, these phenotypes were absent when mutant heavy chains were similarly expressed in a RhoA wild-type background ( Table 3 ), demonstrating that phenotypes were specific to the sensitized, RhoA/+ genetic background and not simply the result of expression of GFP-zip/MyoII mutant heavy chains. Second, phenotypes were only observed in those tissues or cells expressing the transgene (engrailed-expressing;
below the dotted line indicated in Figure 2A ).
Importantly, both the penetrance and expressivity (extent of malformation of the legs and wings) of phenotypes when MYH9-like zip/MyoII mutant heavy chains were expressed were in all cases greater than when GFP-zip/MyoII WT was expressed. The incidence of malformed flies when GFP-zip/MyoII WT was expressed in a RhoA background (4%) is comparable to the rate of malformed flies observed in heterozygous RhoA E3.10 flies with a wild-type zip background (see Table 1 in 30). In these GFP-zip/MyoII WT expressing flies, only mild malformations of the wings and legs were observed (similar to Figure 2B and 2F). In comparison, much more severe wing and leg phenotypes (similar to Figure 2C , 2D, 2G and 2H) were observed when each MYH9-like mutant heavy chain was similarly expressed. Therefore, both the penetrance of malformed flies and the expressivity of the phenotypes were increased when MYH9-like zip/MyoII mutant heavy chains were expressed. The malformed wing and leg phenotypes observed are also consistent with phenotypes we have observed when zip/MyoII function was specifically perturbed using other zip/MyoII constructs (e.g., the zip/MyoII tail or the zip/MyoII neck and tail) that were designed and shown to function as dominant negative alleles (Manuscript in preparation and 26).
In sum, we conclude that these MYH9-like zip/MyoII transgenes function as special alleles of zip/MyoII that exhibit second-site noncomplementation characteristics in trans to heterozygosity in certain, other loci.
MYH9-like zip/MyoII heavy chains undergo correct spatial and temporal localization
To understand how these mutations in zip/MyoII have the observed biological effects we ascertained whether or not the mutant heavy chains localize in the correct spatial and temporal distribution. We examined the subcellular localization of each GFP-zip/MyoII mutant heavy chain compared to GFP-zip/MyoII WT during the dorsal closure stage of embryogenesis ( Figure   3 ). To reduce the contribution of endogenous zip/MyoII that remains at dorsal closure stages, we examined GFP-zip/MyoII mutant heavy chains in embryos that were zygotically deficient for zip/MyoII embryos and contain only the small amounts of zip/MyoII that is maternally loaded and perdures until dorsal closure stages (embryos genetically identical to those assayed in Table   2B ). During the dorsal closure stage of embryogenesis zip/MyoII localizes in a characteristic "bars on a string" distribution along the leading edge of dorsal-most cells of the lateral epidermis (26, 32) . Along with F-actin, zip/MyoII forms a contractile supracellular purse string important for dorsal closure completion (26, 32) .
All GFP-zip/MyoII mutant heavy chains had a subcellular distribution that was indistinguishable from GFP-zip/MyoII WT in dorsal-most cells (Figure 3, arrows) showing that all are capable of correct localization. Embryos were observed from just before the onset to the completion of dorsal closure and no differences in the distribution of GFP-zip/MyoII mutant heavy chains in leading edge cells were observed. This suggests that the GFP-zip/MyoII mutant heavy chains act by poisoning endogenous myosin at the site where these proteins usually function.
MYH9-like zip/MyoII heavy chains heterodimerize with endogenous zip/MyoII
We next investigated the ability of mutant heavy chains to dimerize with wild-type heavy chains, a property that has not been determined for any myosin II-related illness. We found that ).
MYH9-like zip/MyoII
MYH9-like mutations in zip/MyoII do not affect assembly or coiled-coil structure
Given the in vivo findings that MYH9-like zip/MyoII mutant heavy chains have partial wild-type activity, that they behave dominantly in certain genetic backgrounds and that they dimerize with endogenous zip/MyoII heavy chains, we investigated the effect that MYH9-like rod mutations in zip/MyoII had on the formation of the coiled-coil myosin tail and its selfassembly into higher-order structures. We cloned the same tail fragment (AA 1109-1972; Figure   1A ) from each of the MYH9-like zip/MyoII heavy chains into a bacterial protein expression vector, expressed protein in E. coli and purified the protein to homogeneity. The fragments were of similar length to previously studied MYH9 tail fragments (AA 1102 (AA -1961 . We used circular dichroism and electron microscopy of negatively stained specimens and found that α-helices folded into coiled-coil structures and that those structures could in turn assemble into paracrystals comparable to their wild-type counterparts (data presented in Supplemental Material).
Discussion
We have evaluated the efficacy of analyzing the molecular basis of MYH9-related disorders using Drosophila melanogaster as a model system. Under appropriate genetic conditions, substitution of analogous residues in zip/MyoII with any one of four gene lesions (three single amino acid substitutions and one truncation) that cause MYH9-related disorders in humans causes mild dominant phenotypes in D. melanogaster. This suggests that these mutations recapitulate a key feature of the human disorder in this model system. In humans, the dominant phenotypes are so mild that they are frequently discovered only when routine blood smears are performed on patients who present with symptoms due to completely unrelated maladies. In flies, dominant phenotypes are observed in genetic backgrounds that are known to compromise zip/MyoII function. We assert that it would be unlikely to detect mild phenotypes in flies similar to the hematologic manifestations seen in humans -we simply cannot monitor either the structure (anatomy and histology), or the function (physiology) of flies as carefully as we do human patients.
The inability of some embryos to complete development and eclose as adult flies even when the GFP-zip/MyoII WT construct was expressed (Table 2B) is likely the result of the Gal4-UAS expression system and not a result of the biology of GFP-zip/MyoII. We previously showed (26) (19) . One possibility is that differences in dimerization or assembly of the mutant proteins might be revealed in the future if we performed a more exhaustive exploration of "solution" space in which to perform the analysis of dimerization and assembly. pH, ionic strength, the concentration of divalent cations and the presence of certain anions can all influence the dimerization or assembly of other myosin II heavy chains (33) . Alternatively, while the human and D. melanogaster myosin II tails are conserved overall (especially at the amino acid residues studied here, see Figure 1B -E), there are indeed differences in amino acid sequence between the two heavy chains such that the fragments are 52% identical and 76% similar. It is possible that zip/MyoII may accommodate these point mutations better than MYH9 such that CD spectroscopy and electron microscopy on negatively stained specimens do not have the sensitivity to detect more subtle structural abnormalities.
While the function of MYH9-like mutations in zip/MyoII is clearly perturbed in vivo, the effects of these substitutions on dimerization or assembly may simply be too slight to measure in vitro. In vitro studies on mouse and human HMM fragments showed that the dominant, MYH9-like mutations engineered in the motor domain of mouse nonmuscle myosin IIC (Myh14; R722C
and R730C) and human nonmuscle myosin IIB (MYH10; N93K and R709C) cause defects in the enzymatic properties and actin filament sliding compared to wild type (18) . In addition, the protein encoded by at least one of these mutations (MYH10; R709C) was able to poison wildtype myosin-mediated actin filament sliding in vitro. Moreover, the in vivo effect (dominant versus recessive) of these mutations is unknown. Takeda et al., and Ma et al., studied the in vivo effects of knocking-in a mutation analogous to the R702C MYH9-related disorder mutation into the mouse nonmuscle myosin IIB (Myh10; R709C) locus (36, 37) . Heterozygous knock-in mice displayed no observable phenotypes, indicating that this MYH9-like mutation in Myh10 does not act dominantly. Several defects were found in mice homozygous for the R709C mutation, including abnormal gait, difficulties in maintaining balance and defects in neuronal migration in the brain and face (37) . These findings are consistent with our study and show that the R702C
MYH9-like mutation in the mouse Myh10 locus behaves recessively. Together, these results indicate that MYH9-related disorder mutations are extraordinarily unique and specific.
Nonmuscle myosin II heavy chains, including both MYH9 and zip/MyoII, diverged after nonmuscle and muscle myosin II heavy chain isoforms diverged (38) . In other words, the MYH9
and zip/MyoII nonmuscle myosin II genes share a common ancestor more recently than MYH9 does with any human muscle myosin II heavy chain. Given our findings, it seems unlikely that any disease-causing mutation in a human muscle myosin II heavy chain would be homologous to any of the MYH9 rod mutations studied here. We aligned all human myosin II heavy chains and found that none of the four MYH9 rod residues studied here have analogous residues in human muscle myosin II heavy chains that are associated with a pathology. Further, we searched the alignment for all identified point mutations in MYH9-related disorder families (13 in total; 6 in the head and 7 in the rod) and found that only one mutation in MYH9 (AA 702, described in the Introduction) had an analogous mutation in a different human myosin II heavy chain associated with a pathology (AA 726 in MYH14). Interestingly, both genes encode nonmuscle heavy chains (MYH9 encodes nonmuscle myosin IIA and MYH14 encodes nonmuscle myosin IIC).
Together, these findings indicate that each sub class (skeletal muscle, cardiac muscle and nonmuscle isoforms) of myosin II heavy chain harbor specific amino acid residues that are particularly susceptible to mutations that result in dominant behavior. Identification of additional disease-causing mutations in different myosin II heavy chain loci will be necessary to better understand the specificity of these mutations. As this study has focused on MYH9 rod mutations, it is not possible to rule out that MYH9-like mutations in the head region (which is more highly conserved) of zip/MyoII may result in dominant heavy chains. Indeed, Bejsovec and Anderson showed that conserved residues in a muscle myosin head from C. elegans would mutate to dominance (39) .
In sum, our results show that amino acid conservation between two nonmuscle myosin II heavy chains in humans and flies make D. melanogaster a useful system for applying genetic methods to understanding myosin function in these diverse organisms. Given the broad clinical spectrum and severity of myosin II-related pathologies this work suggests that rapid genetic screening approaches in D. melanogaster might be used to investigate myosin function in human pathologies. . Transgenic flies were generated by standard protocols (42) . each genotype were performed in triplicate (therefore, the total number of animals assayed for each genotype was at least 300) and the average and standard deviation was calculated and shown above. 
Materials and Methods
Cloning of mutant GFP-zip/MyoII
Genetic interaction study using MYH9-like zip/MyoII mutant heavy chains
Localization of MYH9-like zip/MyoII mutant heavy chains during dorsal closure
Rescued embryos (as described above) were staged for dorsal closure and mounted for time lapse as previously described (43 The α-rabbit IgG blot verifies that GFP antibodies were both added to the lysate and immunoprecipitated. w 1118 control demonstrates that under these solution conditions all 
